SIX3 and glioblastoma: Higher levels of SIX3 were associated with decreased tumor proliferation and metastasis, leading to better survival outcomes and/or prognosis in breast cancer (Zheng et al., 2018), astrocytoma (Yu et al., 2017), glioblastoma (Zhang B. et al., 2017), and lung adenocarcinoma (Mo et al., 2013).